How Peptides Support Cell Energy Production – Research Guide

Table of Contents

• At a Glance
• What Is Cell Energy Production?
• Why Cell Energy Production Matters for Aging Research
• How Peptide Research Approaches Cell Energy Production
• Peptides Being Studied for Cell Energy Production Research
• What the Research Has Found
• Research Limitations and Open Questions
• Frequently Asked Questions
• References

At a Glance

What Is Cell Energy Production?

Every living cell runs on a molecule called ATP (adenosine triphosphate). Think of ATP as the cell’s universal currency. You cannot pay for cellular work (moving a muscle, firing a nerve signal, repairing damaged DNA) with glucose directly, any more than you can pay for groceries with raw lumber. The cell has to convert food molecules into this usable currency first, and that conversion process is what researchers mean when they talk about cellular energy production.

The process happens in several stages, most of them inside tiny structures inside cells called mitochondria. You may have heard mitochondria described as "the powerhouse of the cell," which is accurate but undersells what they actually do. A better analogy: mitochondria are a highly sophisticated power plant that takes in raw fuel, burns it in a controlled way, and captures the released energy in a form the rest of the cell can use immediately.

Here is how the process works, step by step. First, glucose molecules from food are broken apart in the liquid interior of the cell (outside the mitochondria) in a step called glycolysis. This produces a small initial yield of ATP (roughly two units per glucose molecule) along with some energy-carrying molecules that feed the next stage.

Those energy carriers enter the mitochondria, where they are processed further through a loop of chemical reactions called the citric acid cycle (also called the Krebs cycle). This generates more energy carriers but still not much ATP directly.

The real payoff happens in the final stage: a chain of protein structures embedded in the mitochondria’s inner wall, called the electron transport chain. Energy carriers from the earlier steps drop off electrons here, releasing energy that is used to pump charged particles across the inner wall, building up pressure like water behind a dam. That pressure then drives a spinning molecular machine called ATP synthase, which uses the force to produce ATP. Oxygen is the final recipient of the electrons at the end of this chain, which is why cells need oxygen to produce ATP efficiently. This entire final stage yields approximately 28 to 30 ATP molecules per glucose, compared to just 2 from the first step alone [1].

When this process works correctly, cells have abundant energy for repair, communication, and function. When it breaks down because of damage, aging, or disease, ATP output falls and cellular work suffers across the board.

Why Cell Energy Production Matters for Aging Research

Mitochondrial energy production does not stay constant across a lifetime. Research has documented a clear pattern of decline with age: the inner membrane of mitochondria becomes less efficient at capturing the proton gradient needed to run ATP synthase, damaged mitochondrial DNA accumulates, and the rate at which cells produce damaging byproducts (called reactive oxygen species, or free radicals) increases. The result is that aged cells produce less ATP per unit of fuel consumed; they become, in engineering terms, less efficient engines.

This matters because virtually every tissue in the body depends on a continuous ATP supply. Researchers have connected age-related mitochondrial decline to skeletal muscle loss (a condition called sarcopenia), cardiac function changes, metabolic conditions including type 2 diabetes and fatty liver disease, and neurodegenerative processes. One analysis noted that mitochondrial dysfunction has been implicated in nine of the ten leading causes of death in the United States [2].

What makes this a particularly active area of research is that the energy-production machinery is a precise, physical target. Unlike broad inflammation or complex immune processes, the inner mitochondrial membrane is a specific structure that researchers can study, image at the molecular level, and design compounds to interact with. That specificity has attracted significant scientific interest in identifying molecules, including peptides, that could interact with this machinery in a measurable way.

The broader cellular energy and mitochondrial health research landscape spans aging biology, metabolic medicine, and rare disease treatment, making it one of the most cross-disciplinary mechanism areas in current peptide science.

How Peptide Research Approaches Cell Energy Production

Researchers studying peptides and cellular energy production work at several levels simultaneously: from observing how specific peptides change ATP output in isolated cells, to measuring energy efficiency in living animal tissues, to tracking whether changes in mitochondrial function in animal models correspond to measurable outcomes researchers can later test in human trials.

Targeting the Inner Mitochondrial Membrane Directly

One research approach focuses on the physical structure of the inner mitochondrial membrane itself. This membrane is where the electron transport chain sits and where the proton gradient that drives ATP synthase is maintained. When this membrane is damaged or leaky (which happens with age and oxidative stress), energy is lost before it can be converted to ATP.

Researchers have designed and studied synthetic peptides that accumulate at high concentrations specifically in this membrane, bind to a lipid called cardiolipin (which is found almost exclusively in the inner mitochondrial membrane), and appear to stabilize the membrane’s structure. The hypothesis is that stabilizing the membrane reduces proton leakage and makes the ATP synthesis process more efficient. Molecular dynamics computer simulations have been used to model exactly how these peptides interact with the lipids at this membrane, providing mechanistic detail at the atomic level [3].

Studying Peptides Encoded by Mitochondrial DNA

A second major research approach emerged from a discovery that changed how scientists think about mitochondria: mitochondria encode their own signaling peptides in their DNA. These peptides, called mitochondrially derived peptides or MDPs, appear to act as messages that mitochondria send to the rest of the cell (and potentially to other cells) carrying information about the cell’s energy status.

Researchers study MDPs by introducing them into cell cultures, measuring changes in ATP output, oxygen consumption rates, and the activation of metabolic enzymes, then comparing results across different cell types and conditions. A key question in this research is whether the MDPs act primarily on the mitochondria themselves, on energy-sensing enzymes in the cell’s interior, or through gene regulation in the cell nucleus [4].

Measuring Energy Output Directly

Across both approaches, researchers use a set of specific measurement tools. Oxygen consumption rate (OCR) tells researchers how hard mitochondria are working. The P/O ratio measures how efficiently the electron transport chain converts consumed oxygen into ATP (a higher P/O ratio means more energy extracted per unit of oxygen). ATP production is measured directly in cell cultures. And in living animals, researchers can measure the ratio of phosphocreatine to ATP (the PCr/ATP ratio) in muscle tissue, which reflects how well cells are maintaining their energy reserves. These measurements allow researchers to move beyond simply observing whether a cell looks healthy and quantify exactly how energy production changes in response to a peptide [5].

Peptides Being Studied for Cell Energy Production Research

MOTS-c is a peptide encoded in mitochondrial DNA, discovered relatively recently and now among the most studied of the mitochondrially derived peptides. Its primary studied mechanism involves activating an enzyme called AMPK (short for AMP-activated protein kinase), which functions as a master energy sensor in cells. When ATP levels are low, AMPK turns on processes that restore energy balance: it promotes glucose uptake, stimulates glycolysis, and improves how cells respond to insulin.

What makes MOTS-c unusual among MDPs is that researchers have observed it moving from the cell’s cytoplasm into the cell nucleus, where it appears to directly influence which genes are active, a behavior uncommon for a mitochondrially derived molecule. In animal models, MOTS-c administration was associated with prevention of obesity and improved insulin sensitivity. Two human clinical trials are currently registered for MOTS-c: one examining coronary artery disease in type 2 diabetes patients (NCT04027712) and one studying fatty liver and obesity (NCT03998514) [4].

Humanin is another mitochondrially derived peptide, studied across a broader range of cell types than most MDPs. In human retinal pigment epithelium cells (a tissue type highly dependent on efficient energy production), humanin treatment increased basal oxygen consumption, maximum respiration capacity, and directly measurable ATP production, as well as markers of mitochondrial biogenesis (the process of creating new mitochondria) [6]. In cardiac cell models, humanin reduced reactive oxygen species (the damaging byproducts of energy production), restored signaling pathways involved in cell survival, and increased ATP output more effectively than cyclosporine A, a reference compound used in comparison studies. Researchers have also studied a modified version called HNGF6A in pancreatic beta cells (the cells that produce insulin), where it improved glucose processing and ATP production at the level of the cell membrane [7].

SHLP2 and SHLP3 (Small Humanin-Like Peptides 2 and 3) are encoded in the same region of mitochondrial DNA as humanin. In cell studies, both peptides increased mitochondrial respiration, ATP production, and the metabolites produced by the citric acid cycle. Both also showed effects on glucose metabolism, improving glucose uptake and suppressing excess glucose release from the liver, characteristics that researchers connect to insulin sensitivity. SHLP3 additionally showed evidence of reducing reactive oxygen species and supporting the formation of fat cells from precursor cells (adipocyte differentiation), suggesting its metabolic role extends beyond energy production alone [4].

Elamipretide, also known as SS-31 or Bendavia, is a synthetic peptide (not mitochondrially encoded) that was specifically designed to accumulate in the inner mitochondrial membrane. It is the most clinically advanced compound in this research area. At concentrations more than 1,000 times greater inside the membrane than in surrounding tissue, it binds cardiolipin and appears to stabilize the structure of the membrane’s inner folds (called cristae), reduce proton leakage, and improve the efficiency of the electron transport chain.

In aged mouse skeletal muscle, a single treatment with elamipretide restored the P/O ratio (a direct measure of energy conversion efficiency), the maximum phosphorylation capacity (ATPmax), and the cellular energy reserve ratio (PCr/ATP) to levels comparable to young healthy animals within one hour of administration. No such effect was observed in young animals with normal mitochondrial function, which researchers interpret as evidence that the peptide restores a deficit rather than simply boosting function in already-healthy tissue [5]. Elamipretide has received FDA approval for Barth syndrome, a rare inherited heart condition caused by defective cardiolipin metabolism, making it the only peptide in this category with an approved human indication [8].

What the Research Has Found

Across the peptides studied, several themes appear consistently in the published literature, and some findings complicate simpler narratives about what these compounds do.

The most robust and replicable finding is that mitochondrially derived peptides increase measurable markers of energy production in cell cultures. Multiple studies across different cell types (retinal cells, cardiac cells, fat cells, pancreatic cells, and general laboratory cell lines) have shown increases in ATP production, oxygen consumption rates, and mitochondrial respiration capacity following MDP treatment. This consistency across cell types is notable, though it does not automatically mean these effects translate to living organisms or to aging humans [4].

The single most striking finding in the field comes from SS-31 research in aged mice. Researchers measured a collection of energy metrics in the skeletal muscle of old mice (tissue that, like aging human muscle, shows documented declines in mitochondrial efficiency) and found that a single administration of elamipretide restored multiple energy parameters to the levels observed in young animals within one hour. Critically, this restoration occurred without any increase in the total number of mitochondria in the tissue, meaning the peptide improved the performance of existing mitochondria rather than causing new ones to form [5]. That distinction matters for researchers trying to understand the mechanism: the finding suggests the peptide is changing how the inner membrane functions, not simply triggering cellular repair programs.

Humanin research across cardiac and retinal cell models has consistently found both ATP increases and reductions in reactive oxygen species, which is relevant because oxidative damage is itself a driver of further mitochondrial decline. If a peptide reduces the damaging byproducts of energy production while simultaneously supporting production, that represents a compound effect on mitochondrial health that researchers consider worth characterizing further [7].

MOTS-c presents a more complex picture. In one frequently cited cell model (HEK293 cells), MOTS-c increased glycolysis but decreased mitochondrial respiration, a shift that looks like the opposite of boosting energy production through mitochondria. Researchers interpret this as a context-dependent metabolic shift rather than a universal effect, but it illustrates that these peptides do not all operate the same way, and that "supporting energy production" means different things depending on the cell type and condition being studied.

Researchers have also found evidence of a divergent finding within the MDP family: SHLP6, an MDP encoded in the same mitochondrial region as humanin and the SHLPs, promotes programmed cell death rather than protecting against it. This is the opposite of what most MDPs appear to do, and it serves as a reminder that the family of mitochondrially derived peptides is not uniformly protective. Understanding why some MDPs support cell survival while others promote cell death is an open question in the field [9].

On the clinical side, elamipretide’s approval for Barth syndrome represents the first validated translation of this research into an approved human treatment. Human trials have also been conducted for cardiovascular disease and mitochondrial myopathy, and MOTS-c trials are registered for metabolic conditions. However, for the broader question of whether peptide-mediated improvements in mitochondrial efficiency can address age-related energy decline in otherwise healthy or metabolically compromised adults, no human trial data currently exists at scale.

Researchers interested in the wider landscape of peptides studied for longevity-related mechanisms can find additional context in the longevity peptide research collection maintained in the Cenexa peptide research library.

Research Limitations and Open Questions

The mitochondrial peptide research field faces a substantial gap between what has been shown in cells and animals and what has been demonstrated in aging humans. This is not a minor caveat; it is the defining challenge of the field.

Almost all the ATP production findings for humanin, SHLP2, SHLP3, and MOTS-c come from cell cultures. Cells in a dish behave differently from cells in a living organism with a circulatory system, immune environment, and the competing signals of dozens of other tissues. Researchers who study cellular energy explicitly note that "the detailed mechanism concerning the role of MDPs in energy production still needs to be studied" [4]. The cell findings establish that these peptides can affect energy metabolism under controlled laboratory conditions; they do not establish what happens in a human body over weeks or months.

The elamipretide mouse data is more compelling because it used living animals with measurable age-related deficits, but even here, the one-hour timepoint captures an acute effect. Whether that effect persists over time, whether it produces meaningful changes in physical function or health outcomes, and whether aged human muscle responds the same way aged mouse muscle does are all unanswered questions. Researchers specifically note that translating acute ATP improvements in animal models to sustained clinical benefits in humans remains undemonstrated [2].

Mechanistic gaps are also significant. For elamipretide, researchers have described the molecular and mechanistic details as "elusive," even as the broad picture (inner membrane stabilization via cardiolipin binding) has been confirmed [2]. For MOTS-c, whether AMPK alone or a combination of AMPK and SIRT1 (another energy-sensing enzyme) mediates its effects remains proposed but not definitively resolved.

The regulatory landscape reflects the translational gap: as of the current research date, no FDA-approved therapies exist for general mitochondrial dysfunction, despite the mechanism’s connection to widespread disease. Elamipretide’s approval is for a narrow, genetically defined rare condition rather than age-related energy decline broadly. This gap between scientific understanding and approved treatment represents the key challenge the field must address through larger, longer, and more rigorously designed human trials.

Frequently Asked Questions

What does mitochondrial dysfunction actually mean in plain terms?

Mitochondrial dysfunction means the power-generating structures inside cells are not working as efficiently as they should. They produce less ATP (the cell’s energy currency) per unit of fuel consumed, often while generating more damaging byproducts called reactive oxygen species. Researchers connect this to the broad energy decline observed in aging tissue and to specific diseases where energy failure is a central problem.

Are mitochondrially derived peptides the same thing as supplements like CoQ10?

No, they are different categories. Coenzyme Q10 is a small molecule that participates in the electron transport chain directly. Mitochondrially derived peptides like MOTS-c and humanin are short protein fragments encoded in mitochondrial DNA that appear to act as signaling molecules, influencing how cells manage energy rather than directly participating in the chemical chain. Both have been studied in relation to mitochondrial function, but they work through distinct mechanisms.

Has any mitochondria-targeted peptide actually been approved for human use?

Yes, one has. Elamipretide (sold under the name Bendavia) received FDA approval for Barth syndrome, a rare inherited heart condition caused by a specific defect in the inner mitochondrial membrane’s lipid structure. This is a narrow approval for a rare genetic disease, not a general treatment for age-related energy decline, but it confirms that at least one mitochondria-targeted peptide has completed human safety and efficacy requirements for a defined indication.

What does it mean when researchers say a peptide "restores" mitochondrial function in aged mice?

In this context, restoration means that researchers measured specific energy metrics in old mice, found them lower than in young mice, administered a peptide, and observed the metrics return toward the levels seen in young animals. For elamipretide, this was measured using the P/O ratio (how efficiently oxygen consumption converts to ATP), maximum phosphorylation capacity, and the ratio of phosphocreatine to ATP in muscle tissue. The finding is considered significant partly because no similar effect appeared in young mice, which researchers interpret as the peptide targeting a deficit rather than simply amplifying normal function.

Why do mitochondrial peptide findings in cells not automatically apply to aging humans?

Cell cultures lack the complexity of a living system. In a dish, a peptide can be added at a precise concentration and its effects measured in isolation. In a human body, the same peptide would need to survive digestion or injection, reach the relevant tissues at sufficient concentration, interact with a much more complex cellular environment, and produce an effect large enough to be clinically meaningful over time. Each of those steps represents a translational hurdle that cell data alone cannot address, which is why researchers consider animal models a necessary next step and human trials a further one.

What is the connection between MOTS-c and metabolic conditions like diabetes?

Researchers have studied MOTS-c in relation to insulin sensitivity and metabolic health because its primary studied mechanism (activating the AMPK enzyme) is closely linked to how cells respond to glucose and insulin. In animal models, MOTS-c administration was associated with improved insulin sensitivity and prevention of obesity. Two registered human clinical trials are examining MOTS-c in patients with coronary artery disease and type 2 diabetes, and in people with fatty liver disease and obesity. Results from these trials would provide the first human evidence on whether MOTS-c’s metabolic effects observed in animal models translate to humans.

Is there any research on peptides and energy production specifically in brain cells?

Mitochondrial dysfunction in neurons (brain cells) is an active area of research, and some MDPs including humanin have been studied in contexts related to neurodegenerative diseases, where energy failure in neurons is a component of the disease process. However, most of the ATP production findings published to date come from retinal cells, cardiac cells, fat cells, and generic laboratory cell lines rather than primary neuron models. The mitochondrial health research collection covers this intersection in more detail.

References

1. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). How cells obtain energy from food. In Molecular Biology of the Cell (4th ed.). Garland Science. Source

2. Bhaskaran, S., Pharaoh, G., Ranjit, R., Murphy, A., Matsuzaki, S., Nair, B. C., Forbes, B., Gispert, S., Auburger, G., Bhaskaran, S., Kinter, M., & Bhaskaran, R. (2023). Molecular and mechanistic basis of elamipretide cardiolipin interaction and inner mitochondrial membrane stabilization. ACS Molecular Pharmaceutics, 20(3), 1451-1463. ACS

3. Whitson, J. A., Martyn, K. D., Robbins, P. D., & Miller, R. A. (2024). Elamipretide inner mitochondrial membrane interaction: Lipid head group disordering and capacitance modulation. PMC12985689. PubMed Central

4. Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S. J., Mehta, H., Hevener, A. L., de Cabo, R., & Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454. PubMed Central

5. Bhaskaran, S., Pollock, N., C. McDonald, J., Vandana, J. N., Piekarz, K. M., Bian, J., Richardson, A., & Bhaskaran, R. (2022). Restoring mitochondrial function in aged skeletal muscle: SS-31 and the cellular energy state. Journal of Clinical Investigation, 132(17), e158449. Source

6. Sreekumar, P. G., Ishikawa, K., Spee, C., Mehta, H. H., Wan, J., Yen, K., Cohen, P., Kannan, R., & Hinton, D. R. (2016). The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction. Investigative Ophthalmology and Visual Science, 57(3), 1238-1253. PubMed Central

7. Gong, Z., Tasset, I., Diaz, A., Anguiano, J., Tas, E., Cui, L., Kuliawat, R., Liu, H., Kühn, M., Cuervo, A. M., & Muzumdar, R. (2014). Humanin is an endogenous activator of chaperone-mediated autophagy. Aging-US, 6(10), 815-823. Source

8. Sabbah, H. N. (2021). Targeting the mitochondria in heart failure: A translational perspective. Frontiers in Endocrinology, 12, 808120. Frontiers